IGC Pharma Inc. has used its artificial intelligence (AI) modeling to identify the company’s proprietary molecule, IGC-1A, as a potential GLP-1 agonist. The company’s AI model compared IGC-1A and IGC-1C to established drugs such as Ozempic (semaglutide), tirzepatide, retatrutide and metformin, among others, and indicated that they could become effective options for metabolic disorders.
The risk of developing multiple sclerosis (MS) is nearly four times as high for women as it is for men. And that relative risk has increased sharply over time. In 1955, women were only slightly more likely than men to develop MS. A research team at the University of Toronto and the Oklahoma Medical Research Foundation (OMRF) has gained new insights into possible causes for this increasing disparity.
Thyroid hormones are involved in growth, development and metabolism processes. The thyroid hormone receptor β (THRβ) isoform, mainly expressed in the liver, is responsible for the reduction of cholesterol levels and thus is considered a therapeutic target for the treatment of dyslipidemia, obesity and related disorders.
Boehringer Ingelheim Pharma GmbH & Co KG has identified drug conjugates acting as neuromedin U receptor 2 (NMU2) agonists reported to be useful for the treatment of obesity.
Recent findings suggest gut microbiota dysbiosis may be behind the inflammation in diabetic nephropathy (DN), the leading cause of end-stage renal disease (ESRD).
Arrowhead Pharmaceuticals Inc. announced its plans to advance its RNAi drug candidates ARO-INHBE and ARO-ALK7 into clinical trials for the treatment of obesity and metabolic diseases.
The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has discovered glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes and obesity, among others.
The University of Florida has prepared and tested PPARγ agonists reported to be useful for the treatment of diabetes, hyperparathyroidism, metabolic syndrome, multiple myeloma, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), obesity, osteoporosis and Paget disease, among others.
Zyversa Therapeutics Inc. announced it has selected obesity and its related metabolic complications as the lead indication for its ASC protein inhibitor IC-100. One consequence of high weight is chronic inflammation, which increases the risk of multiple metabolic and cardiovascular disorders.
Scientists at Boehringer Ingelheim GmbH have made the ketohexokinase (KHK) inhibitor BI-9787 freely available as a tool compound via the company’s Opnme program.
RSS
